Last reviewed · How we verify
NCT06343766
Polymorphisms in ENAM, AMBN, and KLK4 Contribute to DCS.
trial testing DNA collation and genotyping in Dental Caries Secondary to Polymorphisms in 204 participants. Completed in 5 November 2023.
5 November 2023
Quick facts
| Lead sponsor | Amina Fouad Farag |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 204 |
| Start date | 6 November 2022 |
| Primary completion | 5 November 2023 |
| Estimated completion | 5 November 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- DNA collation and genotyping
Conditions studied
- Dental Caries Secondary to Polymorphisms — all drugs for Dental Caries Secondary to Polymorphisms →
- Polymorphisms in Enamel Encoding Genes — all drugs for Polymorphisms in Enamel Encoding Genes →
Sponsor
Amina Fouad Farag
Who can join
Adults 15 to 22, any sex, with Dental Caries Secondary to Polymorphisms or Polymorphisms in Enamel Encoding Genes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Cross-Sectional Study aims to shed light on potential genetic determinants influencing dental caries susceptibility within this demographic and significantly understanding of genetic factors associated with dental caries, particularly within the context of the Egyptian population, providing valuable insights into the genetic aspects of oral health. The research methodology involved a comprehensive examination of these polymorphic loci ENAM, AMBN, TUFT1 and KLK4 and their prevalence, employing rigorous statistical analyses to establish potential correlations between these genetic variants and susceptibility to dental caries.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06343766
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Amina Fouad Farag trials
Trials by the same sponsor.
- NCT04907422 — Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06343766 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amina Fouad Farag
- Last refreshed: 3 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06343766.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing